68Ga-PSMA-617 PET/CT. A promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients
Creators
- 1. Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Beijing (China)
- 2. Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Urology, Beijing (China)
- 3. Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Beijing (China)
- 4. Beijing Hospital, Department of Urology, Beijing (China)
- 5. Peking University First Hospital, Department of Urology, Beijing (China)
- 6. Peking University First Hospital, Department of Nuclear Medicine, Beijing (China)
- 7. Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Ultrasonography, Beijing (China)
Description
The purpose of this study was to investigate the performance of 68Ga-PSMA-617 PET/CT in predicting risk stratification and metastatic risk of prostate cancer. Fifty newly diagnosed patients with prostate cancer as confirmed by needle biopsy were continuously included, 40 in a train set and ten in a test set. 68Ga-PSMA-617 PET/CT and clinical data of all patients were retrospectively analyzed. Semi-quantitative analysis of PET images provided maximum standardized uptake (SUVmax) of primary prostate cancer and volumetric parameters including intraprostatic PSMA-derived tumor volume (iPSMA-TV) and intraprostatic total lesion PSMA (iTL-PSMA). According to prostate cancer risk stratification criteria of the NCCN Guideline, all patients were simplified into a low-intermediate risk group or a high-risk group. The semi-quantitative parameters of 68Ga-PSMA-617 PET/CT were used to establish a univariate logistic regression model for high-risk prostate cancer and its metastatic risk, and to evaluate the diagnostic efficacy of the predictive model. In the train set, 30/40 (75%) patients had high-risk prostate cancer and 10/40 (25%) patients had low-to-moderate-risk prostate cancer; in the test set, 8/10 (80%) patients had high-risk prostate cancer while 2/10 (20%) had low-intermediate risk prostate cancer. The univariate logistic regression model established with SUVmax, iPSMA-TV and iTL-PSMA could all effectively predict high-risk prostate cancer; the AUC of ROC were 0.843, 0.802 and 0.900, respectively. Based on the test set, the sensitivity and specificity of each model were 87.5% and 50% for SUVmax, 62.5% and 100% for iPSMA-TV, and 87.5% and 100% for iTL-PSMA, respectively. The iPSMA-TV and iTL-PSMA-based predictive model could predict the metastatic risk of prostate cancer, the AUC of ROC was 0.863 and 0.848, respectively, but the SUVmax-based prediction model could not predict metastatic risk. Semi-quantitative analysis indexes of 68Ga-PSMA-617 PET/CT imaging can be used as ''imaging biomarkers'' to predict risk stratification and metastatic risk of prostate cancer. (orig.)
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00259-018-4037-9Additional details
Identifiers
Publishing Information
- Journal Title
- European Journal of Nuclear Medicine and Molecular Imaging
- Journal Volume
- 45
- Journal Issue
- 11
- Journal Page Range
- p. 1852-1861
- ISSN
- 1619-7070
- CODEN
- EJNMA6
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 50000230
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ACCURACY; ANTIGENS; BIOLOGICAL MARKERS; BIOPSY; CARCINOMAS; COMPUTERIZED TOMOGRAPHY; GALLIUM 68; HISTOLOGY; METASTASES; POSITRON COMPUTED TOMOGRAPHY; PROSTATE; RADIOPHARMACEUTICALS; RECOMMENDATIONS; REGRESSION ANALYSIS; SENSITIVITY; SPECIFICITY; SURGERY; UPTAKE
- Descriptors DEC
- BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BODY; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DISEASES; DRUGS; ELECTRON CAPTURE RADIOISOTOPES; EMISSION COMPUTED TOMOGRAPHY; GALLIUM ISOTOPES; GLANDS; HOURS LIVING RADIOISOTOPES; INTERMEDIATE MASS NUCLEI; ISOTOPES; LABELLED COMPOUNDS; MALE GENITALS; MATERIALS; MATHEMATICS; MEDICINE; NEOPLASMS; NUCLEI; ODD-ODD NUCLEI; ORGANS; RADIOACTIVE MATERIALS; RADIOISOTOPES; STATISTICS; TOMOGRAPHY